1-3 of 3
Sarah Cadot
Close
Sort by
Journal Articles

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

Anne Calleja, Sandra De Barros, Camille Vinson, PharmD, Caroline Protin, MD, Lucie Oberic, MD, Fanny Gallais, Melanie White-koning, Etienne Chatelut, Christian Recher, MD PhD, Sarah Cadot, PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Fabien Despas, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3960.
https://doi.org/10.1182/blood-2018-99-116532
Published: 2018
Journal Articles

Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach

Loic Ysebaert, MD PhD, Sarah Cadot, PhD, Salim Kanoun, MD, Soleakhena Ken, Christian Recher, MD PhD, François Malgouyres, Sebastien Gadat, Loic Dupre, PhD, Anne Quillet Mary, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2990.
https://doi.org/10.1182/blood.V130.Suppl_1.2990.2990
Published: 2017
Journal Articles

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

Brief Report
Marie Levade, Elodie David, Cédric Garcia, Pierre-Alexandre Laurent, Sarah Cadot, Anne-Sophie Michallet, Jean-Claude Bordet, Constantine Tam, Pierre Sié, Loïc Ysebaert, Bernard Payrastre
Journal: Blood
Blood (2014) 124 (26): 3991–3995.
https://doi.org/10.1182/blood-2014-06-583294
Published: 2014
Includes: Multimedia, Supplemental data